Alnylam to Webcast Presentation at 19th Annual Needham Virtual Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Outlook Therapeutics (OTLK) halted, news pending
Alnylam Pharmaceuticals (ALNY) PT Raised to $202 at Cantor Fitzgerald Following Announced Blackstone Deal
April 14, 2020 7:03 AM EDTCantor Fitzgerald analyst Alethia Young raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $202.00 (from $195.00) while maintaining a Overweight rating following the Blackstone (NYSE: BX) deal announced on April 13th. The deal is centered around the inclisiran royalty. Investor... More
